Antibiotic resistant bloodstream infections in pediatric patients receiving chemotherapy or hematopoietic stem cell transplant: factors associated with development of resistance, intensive care admission and mortality
Author
dc.contributor.author
Castagnola, Elio
Author
dc.contributor.author
Bagnasco, Francesca
Author
dc.contributor.author
Mesini, Alessio
Author
dc.contributor.author
Agyeman, Philipp K. A.
Author
dc.contributor.author
Ammann, Roland A.
Author
dc.contributor.author
Carlesse, Fabianne
Author
dc.contributor.author
Santolaya de Pablo, Maria Elena
Author
dc.contributor.author
Groll, Andreas H.
Author
dc.contributor.author
Haeusler, Gabrielle M.
Author
dc.contributor.author
Lehrnbecher, Thomas
Author
dc.contributor.author
Simon, Arne
Author
dc.contributor.author
D’Amico, María Rosaría
Author
dc.contributor.author
Duong, Austin
Author
dc.contributor.author
Idelevich, Evgeny A.
Author
dc.contributor.author
Luckowitsch, Marie
Author
dc.contributor.author
Meli, Mariaclaudia
Author
dc.contributor.author
Menna, Giuseppe
Author
dc.contributor.author
Palmert, Sasha
Author
dc.contributor.author
Russo, Giovanna
Author
dc.contributor.author
Sarno, Marco
Author
dc.contributor.author
Solopova, Galina
Author
dc.contributor.author
Tondo, Annalisa
Author
dc.contributor.author
Traubici, Yona
Author
dc.contributor.author
Sung, Lillian
Admission date
dc.date.accessioned
2022-03-15T21:16:43Z
Available date
dc.date.available
2022-03-15T21:16:43Z
Publication date
dc.date.issued
2021
Cita de ítem
dc.identifier.citation
Antibiotics 2021, 10, 266
es_ES
Identifier
dc.identifier.other
10.3390/antibiotics10030266
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/184210
Abstract
dc.description.abstract
Bloodstream infections (BSI) are a severe complication of antineoplastic chemotherapy or
hematopoietic stem cell transplantation (HSCT), especially in the presence of antibiotic resistance
(AR). A multinational, multicenter retrospective study in patients aged 18 years, treated with
chemotherapy or HSCT from 2015 to 2017 was implemented to analyze AR among non-common skin commensals BSI. Risk factors associated with AR, intensive care unit (ICU) admission and mortality
were analyzed by multilevel mixed effects or standard logistic regressions. A total of 1291 BSIs
with 1379 strains were reported in 1031 patients. Among Gram-negatives more than 20% were
resistant to ceftazidime, cefepime, piperacillin-tazobactam and ciprofloxacin while 9% was resistant
to meropenem. Methicillin-resistance was observed in 17% of S. aureus and vancomycin resistance
in 40% of E. faecium. Previous exposure to antibiotics, especially to carbapenems, was significantly
associated with resistant Gram-negative BSI while previous colonization with methicillin-resistant
S. aureus was associated with BSI due to this pathogen. Hematological malignancies, neutropenia
and Gram-negatives resistant to >3 antibiotics were significantly associated with higher risk of ICU
admission. Underlying disease in relapse/progression, previous exposure to antibiotics, and need
of ICU admission were significantly associated with mortality. Center-level variation showed a
greater impact on AR, while patient-level variation had more effect on ICU admission and mortality.
Previous exposure to antibiotics or colonization by resistant pathogens can be the cause of AR BSI.
Resistant Gram-negatives are significantly associated with ICU admission and mortality, with a
significant role for the treating center too. The significant evidence of center-level variations on AR,
ICU admission and mortality, stress the need for careful local antibiotic stewardship and infection
control programs.
Antibiotic resistant bloodstream infections in pediatric patients receiving chemotherapy or hematopoietic stem cell transplant: factors associated with development of resistance, intensive care admission and mortality